Loading...
On November 29, 2010, Merck announced that it was terminating a randomized phase III trial that compared once-daily versus twice-daily dosing of raltegravir among treatment-naive patients, because the once-daily dosing had failed to meet the criteria for noninferiority. The trial involved 770 patients: About half received 800 mg of raltegravir once daily, while the other half received the FDA-approved dose of 400 mg twice daily; both groups also received tenofovir/FTC. At 48 weeks, viral loads were undetectable in 83.2% of the once-daily group versus 88.9% of the twice-daily group. The difference was most marked in patients with viral loads >100,000 copies/mL (74.3% vs. 84.2%).